TrialDigestion2021

Week 2 Symptomatic Response with Vedolizumab as a Predictive Factor in Japanese Anti-TNFα-Naive Patients with Ulcerative Colitis: A post hoc Analysis of a Randomized, Placebo-Controlled Phase 3 Trial.

Masakazu Nagahori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.